The DOI matches its Crossref record.
Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.
Abstract
PURPOSE: The prognosis of patients with multifocal primary and early or multiple relapsed Ewing's sarcoma is poor with conventional chemoradiotherapy and surgery. We evaluated the efficacy and feasibility of a myeloablative regimen administered as consolidation treatment for these patients. PATIENTS AND METHODS: The ablative regimens consisted of simultaneous radiochemotherapy: 12 Gy hyperfractionated total-body irradiation (TBI; two doses of 1.5 Gy for 4 days) plus fractionated high-dose melphalan (30 to 45 mg/m2 for 4 days) followed by high-dose etoposide (40 to 60 mg/kg) with or without carboplatin (900 to 1,500 mg/m2) (hyper-ME +/- C). These regimens were applied in a dose-escalation study that included 17 patients. All patients underwent remission induction chemotherapy and local treatment before myeloablative therapy. Seven patients had multifocal primary Ewing's sarcoma, and 10 had early or multiple relapse. We performed a matched-cohort analysis of the 17 grafted patients with 41 historic controls matched for sex, age, diagnosis, extent of disease, interval from diagnosis to transplant in the transplant group, and interval from diagnosis to relapse in the control group. RESULTS: The probability of relapse in the study patients is 52% at 6 years after the last event before transplantation. In the control group, the probability of relapse at 6 years was 98%. Eight of 17 treated patients are alive in complete remission at a median observation time of 49 months (range, 19 to 76) from the last event before transplantation. Probability of relapse-free survival in the study patients is 45% +/- 12% at 6 years after the last event before transplant, compared with 2% +/- 2% for the historic control group. CONCLUSION: Myeloblative therapy with hyper-ME +/- C radiochemotherapy can improve the prognosis of multifocal primary and early or multiple relapsing Ewing's sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cotterill, S. J., Ahrens, S., Paulussen, M., Jürgens, H. F., Voûte, P. A., Gadner, H., & Craft, A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3108 · Cited by 1,040
Self-citationCommon Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657
Esiashvili, N., Goodman, M., & Marcus, R. B. (2008) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31816e22f3 · Cited by 582
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial
Ladenstein, R., Pötschger, U., Le Deley, M. C., Whelan, J., Paulussen, M., Oberlin, O., van den Berg, H., Dirksen, U., Hjorth, L., Michon, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9864 · Cited by 540
Self-citationEwing's Sarcoma Family of Tumors: Current Management
Bernstein, M., Kovar, H., Paulussen, M., Randall, R. L., Schuck, A., Teot, L. A., & Juergensg, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-5-503 · Cited by 520
Self-citation
Metadata
- Authors
- Burdach, S., Jürgens, H., Peters, C., Nürnberger, W., Mauz-Körholz, C., Körholz, D., Paulussen, M., Pape, H., Dilloo, D., & Koscielniak, E.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-08
- Volume
- 11
- Issue
- 8
- Pages
- 1482-1488
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1934049722
- Cited by
- 214
- References
- 0
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. https://app.cochat.ai/papers/10.1200/jco.1993.11.8.1482
- The paper
- Burdach, S., Jürgens, H., Peters, C., Nürnberger, W., Mauz-Körholz, C., Körholz, D., Paulussen, M., Pape, H., Dilloo, D., & Koscielniak, E. (1993). Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.8.1482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.